This notice describes how medical information about you may be used and disclosed and how you can get access to this information. Please review carefully.
As part of the federal Health Insurance Portability and Accountability Act (HIPAA), the facility has created this Notice of Privacy Practices. ll1is notice describes the Facility’s privacy practices and the rights you, the individual, have as they relate to the privacy of your Protected Health Information (PHI). Your PHI is information about you, or it could be used to identify you, as it relates to your past and present physical and mental health care services. 111e HIPAA regulations require that the facility protect the privacy of the PHI that the facility has received or created.
This facility will abide by the terms presented within this Notice. For any uses or disclosures that are not listed below (including marketing and selling of PHI), the facility will obtain a written autl1orization from you for that use or disclosure, which you will have the right to revoke at any time, as explained in more detail below. The facility reserves the right to change the facility’s privacy practices and this notice.
ROW THE FACILITY MAY USE AND DISCLOSE YOUR PHI:
The following is an accounting of the ways that the facility is permitted by law to use and disclose your PHI.
Treatments: We will use the PHI that we receive from you to fill your prescription and coordinate your healthcare.
Payment: The facility will disclose your PHI to obtain payment or reimbursement from insurers for your healthcare services.
Healthcare Operations: The facility may use the minimum necessary amount of your PHI to conduct quality assessments, improvement activities, and evaluate the facility workforce.
As required by law this facility is required to use or disclose PHI about you as required and as limited by law.
Public Health Activities: The facility may use or disclose PHI about you to a public health authority that is authorized by law to collect for the purpose of preventing or controlling disease, injury, or disability. This includes the FDA so that it may monitor any adverse effects of drugs, foods, nutritional supplements, and other products as required by Jaw.
Victims of abuse, neglect, or domestic violence: This facility may use or disclose PHI about you to a government authority if it is reasonably believed you are a victim of abuse, neglect, or some violence.
Health Oversight Activities: This facility may use or disclose PHI about you to a health oversight agency for oversight activities which may include audits, investigations, inspectors as necessary for licensure, compliance with civil laws, or other activities the health oversight agency is authorized by law to conduct.
Individuals involved in your care: This facility may disclose PHI about you to individuals involved in your care.
Judicial and Administrative Proceedings: This facility may disclose PHI about you in the course of any judicial or administrative proceedings, provided that proper documentation is presented to the facility.
Law Enforcement Purposes: This facility may disclose PHI about you to law enforcement officials for authorized purposes as required by law or in response to a court order or subpoena.
About the Deceased: This facility may disclose PHI about a deceased, or before, and in reasonable anticipation of an individual’s death, to coroners, medical examiners, and funeral directors.
Cadaveric organ, eye, or tissue donation purposes: This facility may use and disclose PHI for the purpose of procurement, banking, or transplantation of cadaveric organs, eyes, or tissues for donation purposes.
Research purposes: This facility may use and disclose PHI about you for research purposes with a valid waiver of authorization approved by an institutional review board or a privacy board. Otherwise, the facility will request a signed authorization by the individual for all other research purposes.
To avert a serious threat to health or safety: This facility may use or disclose PHI about you if it is believed in good faith and is consistent with any applicable law and standards of ethical conduct to avert serious threats to health or safety.
Specialized Government Functions: ‘Olis facility may use or disclose PHI about you for specialized government functions including, military and veteran’s activities, national security and intelligence, proactive services, department of state functions, and correctional institutions and law enforcement custodial situations.
Workers’ compensation: This facility may disclose PHI about you as authorized by and to the extent necessary to comply with workers’ compensation laws or programs established by law.
Disaster Relief purposes: This facility may disclose PHI about you as authorized by law to a public or private entity to assist in disaster relief efforts and for family and personal representative notification.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 (Glucagon-like peptide-1) receptor agonist that regulates glucose levels and stimulates weight loss by controlling blood glucose and slowing down digestion.
It is FDA-approved for type-2 Diabetes Mellitus and weight-loss management. It will decrease appetite and will cause a person to feel fuller longer. With a lifestyle change consisting of a healthy diet and exercise, it can cause a reduction in body fat by at least 10-20%.
Some of the adverse reactions or side effects may include diarrhea, nausea, vomiting, abdominal pain decreased appetite, indigestion, bloating, gastroesophageal reflex disease (GERD), dizziness, or constipation. Anaphylaxis, skin rash, sinus tachycardia, and hypoglycemia have also been reported. Do not use if hypersensitive to Tirzepatide or with other inactive ingredients.
Do not use past the expiration date or BUD. The injection must be stored in the refrigerator. Keep out of reach of children and do not flush down the drain or sink.
Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1RA). Once it is released into the bloodstream, it improves glycemic control in adults with type 2 diabetes. It is also indicated for weight loss management in conjunction with a healthy diet and exercise regimen. It binds and activates the GLP-1 receptor which is a regulator of glucose homeostasis and is released after ingestion of carbohydrates and fats. GLP-1 enhances insulin secretion from pancreatic beta cells when there is an elevation of glucose.
It also suppresses glucagon secretion, decreases gastric emptying which decreases appetite and decreases A1c. It can be given in combination with Cyanocobalamin (Vitamin B12) or Pyridoxine (Vitamin B6).
Some of the adverse reactions or side effects may include diarrhea, nausea, vomiting, abdominal pain decreased appetite, indigestion, bloating, gastroesophageal reflex disease (GERD), dizziness, or constipation. Anaphylaxis, skin rash, sinus tachycardia, and hypoglycemia have also been reported. Do not use if hypersensitive to Semaglutide or with other inactive ingredients.
Semaglutide is given subcutaneously once weekly. Doses are individually based per patient. It is to be stored in the refrigerator and keep away from heat or light or moisture. Do not use past the expiration date or BUD. Keep out of
reach of children. Dispose of any unused after the beyond use date. Do not flush down the sink or drain.
CJC-1295 and Ipamorelin are two peptides that work synergistically to stimulate the pituitary gland to enhance the release of natural growth hormone (GH) in the body. CJC-1295 is a Growth Hormone-Releasing Hormone (GHRH) analog, with 30 amino acids, that stimulates the anterior pituitary gland to increase GH secretion. It has a long half-life (slow acting), allowing for sustained GH release. Ipamorelin is a growth-hormone-releasing secretagogue that stimulates the pituitary gland to increase GH production and release into the bloodstream to help improve memory, pain, and cognitive skills.
Both CJC-1295 and Ipamorelin affect the pituitary gland in different ways to stimulate increased GH production. CJC-1295 binds pituitary receptors to secrete growth hormone-releasing hormone (GHRH) in the brain and stimulate the pituitary gland to increase growth hormone production. On the other hand, Ipamorelin imitates the properties of ghrelin (which is responsible for the breakdown of fats and prevents muscle deterioration) and binds to ghrelin receptors in the brain to stimulate growth hormone production.
Side effects may include headaches, flu-like symptoms, irritability, anxiety, hives, nausea, and vomiting. Anaphylaxis, skin rash, sinus tachycardia, and injection site pain and swelling have been reported. Do not use if you are hypersensitive to CJC-1295, Ipamorelin, or other ingredients.
CJC/Ipamorelin injection is a subcutaneous injection with dosing and injection frequency determined by the prescriber. Always use medication as directed. Do not use past the listed beyond use date (BUD). Keep the medication refrigerated. Keep out of reach of children and do not flush medication down the sink or drain.
Body Protection Compound (BPC)-157 is a naturally occurring peptide made of 15 amino acids derived from human gastric juices. The peptide naturally occurs in the gut of humans and protects/preserves the lining of the gastrointestinal (GI) tract from the acidity of stomach acid. BPC-157 stimulates vascular endothelia growth factor promoting the formation of blood vessels. BPC-157 can also regulate growth receptors and enhance fibroblast production, playing a role in collagen synthesis.
BPC-157 injections serve a multitude of functions such as, but not limited to; assists the healing process of bone and joint injuries, decreases joint pain, supports cardiovascular health, enhances collagen production, promotes hair and nail growth, and may act as an anti-inflammatory.
Side effects may include headache, nausea, dizziness, vomiting, fatigue, increased appetite, and elevated blood pressure. Anaphylaxis, skin rash, sinus tachycardia, and injection site pain and swelling have been reported. Do not use if you are hypersensitive to BPC-157 or other ingredients.
BPC-157 injection is a subcutaneous injection with dosing and injection frequency determined by the prescriber. Always use medication as directed. Do not use past the listed beyond use date (BUD). Keep the medication refrigerated. Keep out of reach of children and do not flush medication down the sink or drain.